Mammalian metabolites of a tachykinin receptor antagonist

   
   

This invention is concerned with mammalian metabolites of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist that is useful in the prevention and treatment of certain disorders, including emesis and psychiatric disorders such as depression and anxiety.

Diese Erfindung wird mit Säugetier- Stoffwechselprodukten des zusammengesetzten 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(5-oxo-1H, 4H-1, 2, 4-triazolo)methylmorpholine betroffen, welches ein tachykinin Empfängerantagonist ist, der in der Verhinderung und in der Behandlung bestimmter Störungen, einschließlich Erbrechen und psychiatrische Störungen wie Tiefstand und Angst nützlich ist.

 
Web www.patentalert.com

< Carbinols for the treatment of neuropathic dysfunction

< Anti-inflammatory compositions and methods of use

> Herbal composition having antiallergic properties and a process for the preparation thereof

> Methods for identifying ligand binding sites in a biomolecule

~ 00110